Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

The Application of Molecular Genetics in Multiple Thyroids Neoplasia Type 1 Screening

Aarunya Powell

Multiple endocrine neoplasia type 1 (MEN1) is a genetic disorder characterized by the development of tumors in multiple endocrine organs, including the thyroid gland. The application of molecular genetics has revolutionized the screening and diagnosis of MEN1-associated thyroid neoplasia. This abstract provides a concise overview of the key aspects of using molecular genetics in MEN1 screening, including genetic testing, predictive testing, carrier testing, and their prognostic and therapeutic implications. Genetic testing allows for the identification of mutations in the MEN1 gene, confirming the diagnosis of MEN1 and aiding in identifying at-risk family members. Predictive testing detects individuals who have inherited the MEN1 mutation but do not exhibit clinical signs, enabling early detection and preventive measures. Carrier testing helps identify individuals who carry the MEN1 mutation but do not develop the disorder, providing essential information for family planning and genetic counseling. Molecular genetic analysis of MEN1-associated thyroid neoplasms provides insights into prognosis and therapeutic strategies. Certain genetic alterations may indicate a higher risk of aggressive tumor behavior or resistance to specific treatments, guiding personalized treatment plans.